Enveric Biosciences (ENVB) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives. The patented compounds were designed through Enveric’s proprietary discovery platform and represent an approach to non-hallucinogenic psychedelic-inspired therapeutics. The compounds demonstrated low hallucinogenic liability in preclinical testing, including minimal Head Twitch Response and reduced 5-HT2A receptor activation – two established indicators of hallucinogenic activity in rodents.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Psychedelic: atai, Beckly Psytech to combine in all-share transaction
- Enveric Biosciences Holds 2025 Annual Stockholders Meeting
- Enveric gets U.S. patent for sleep, CNS therapeutics
- Enveric Biosciences announces results from EB-003 trial
- Psychedelic: atai Life Sciences reports Phase 2a study data on BPL-003